Neurocrine Bioscienc
(NBIX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2015 | 06-2015 | 03-2015 | 12-2014 | 09-2014 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -59,614 | -25,179 | -1,192 | -60,542 | -41,098 |
| Depreciation Amortization | 5,050 | 3,074 | 1,255 | 4,619 | 3,348 |
| Accounts receivable | N/A | N/A | -30,552 | -1,671 | -1,471 |
| Other Working Capital | 1,844 | 1,004 | -31,211 | 1,609 | 372 |
| Other Operating Activity | 29,926 | 16,879 | 43,517 | 8,845 | 7,018 |
| Operating Cash Flow | $-22,794 | $-4,222 | $-18,183 | $-47,140 | $-31,831 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -216,809 | -169,241 | -115,823 | -103,411 | -119,783 |
| PPE Investments | -1,097 | -781 | -271 | -1,567 | -1,128 |
| Other Investing Activity | 40 | 16 | 0 | -388 | 0 |
| Investing Cash Flow | $-217,866 | $-170,006 | $-116,094 | $-105,366 | $-120,911 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 276,024 | 275,284 | 273,525 | 138,731 | 136,999 |
| Financing Cash Flow | $276,024 | $275,284 | $273,525 | $138,731 | $136,999 |
| Beginning Cash Position | 31,014 | 31,014 | 31,014 | 44,789 | 44,789 |
| End Cash Position | 66,378 | 132,070 | 170,262 | 31,014 | 29,046 |
| Net Cash Flow | $35,364 | $101,056 | $139,248 | $-13,775 | $-15,743 |
| Free Cash Flow | |||||
| Operating Cash Flow | -22,794 | -4,222 | -18,183 | -47,140 | -31,831 |
| Capital Expenditure | -1,106 | -790 | -280 | -1,612 | -1,173 |
| Free Cash Flow | -23,900 | -5,012 | -18,463 | -48,752 | -33,004 |